Replies to post #82152 on $heff's $tation of $tocks & $olid DD

[beach_trades]

$MSTX-Like update this AM and r/r at this point with all the upcoming catalysts

http://finance.yahoo.com/news/mast-therapeutics-provides-corporate-reports-120000464.html
We have an ongoing Phase 3 study in a rare disease with more than an 18-month head start on our nearest competitor. We have an ongoing Phase 2 study that will demonstrate whether MST-188 improves the effectiveness of a thrombolytic agent that's used everywhere from acute limb ischemia to pulmonary embolism to heart attack and stroke. We have another Phase 2 study planned in heart failure, the leading cause of hospitalization in patients over 65. And, we have cash to move these and our other programs towards major value inflection points."

Upcoming News and Events

•Phase 2 Study (pulmonary arterial hypertension): preliminary data

Q3 2014

•Phase 2 Study (heart failure): agreement with FDA on protocol

Q4 2014

•Nonclinical Study (heart failure): data

Q1 2015

•Nonclinical Study (embolic stroke): data

Q2 2015

•Phase 2 Study (heart failure): initiate enrollment

1H 2015

•Phase 2 Study (acute limb ischemia): complete enrollment

Q4 2015

•EPIC Study (sickle cell disease): complete enrollment

Q4 2015

•Phase 2 Study (WHO Group 2 pulmonary hypertension): data

2H 2015

•Phase 2 Study (heart failure): data (interim analysis)

2H 2015

MST-188 – Sickle Cell Disease (SCD)
The Company continues to enroll patients in EPIC, its pivotal Phase 3 study of MST-188 in SCD, and reiterates its prior guidance that enrollment will complete at the end of 2015. MST-188 has orphan drug status for SCD in both the U.S. and EU, as well as fast track status with the FDA.